Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Utility And Predictive Value Of The Crafity Score In Advanced Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitors And Pd-1 Inhibitor

Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Lijie Zhang1,2, Tao Sun1,2, Bo Sun1,2

  • 1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.

BMC Cancer
|February 16, 2024

Related Experiment Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

431
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

View abstract on PubMed

Summary
This summary is machine-generated.

The CRAFITY score predicts outcomes for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), and immunotherapy. A lower CRAFITY score indicates better overall survival and progression-free survival.

Area of Science:

  • Hepatobiliary cancers
  • Oncology
  • Immunotherapy

Background:

  • The CRAFITY score (CRP and AFP in ImmunoTherapY) is prognostic in hepatocellular carcinoma (HCC) patients receiving immunotherapy.
  • Hepatocellular carcinoma (HCC) is a significant global health concern, necessitating improved prognostic tools.

Purpose of the Study:

  • To evaluate the predictive value of the CRAFITY score in HCC patients undergoing transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and immunotherapy.
  • To assess the correlation between CRAFITY score and treatment outcomes, including overall survival (OS), progression-free survival (PFS), and adverse events (AEs).

Main Methods:

  • Retrospective analysis of 70 advanced HCC patients treated with TACE, TKIs, and PD-1 inhibitor (January 2019-June 2022).
  • Patients were stratified into CRAFITY-low (0 points), CRAFITY-intermediate (1 point), and CRAFITY-high (2 points) groups based on CRP and AFP levels.
Keywords:
Hepatocellular carcinomaPD-1 inhibitorTransarterial chemoembolizationTyrosine kinase inhibitors

Related Experiment Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

431
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
  • Comparison of OS, PFS, tumor response (ORR, DCR), and AEs among the groups.

    • Main Results:

    • Lower CRAFITY scores were independently associated with improved OS (P=.045) and PFS (P<.001).
    • The CRAFITY-low group showed a higher objective response rate (ORR) at 3 months; disease control rate (DCR) differed significantly among groups over 12 months.
    • Protein urea was most frequent in the CRAFITY-high group; no significant differences in grade ≥3 adverse events were observed.

    Conclusions:

    • The CRAFITY score is a simple and effective tool for predicting treatment outcomes, tumor response, and adverse events in HCC patients receiving TACE plus TKIs and PD-1 inhibitor therapy.
    • This score can aid in patient stratification and personalized treatment strategies for advanced HCC.